Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
Founded in 2016, Infervision stands at the forefront of AI-driven medical technology, dedicated to enhancing multidisciplinary healthcare services and operations through innovative artificial intelligence solutions. Their advanced AI offerings are designed to assist healthcare professionals across a spectrum of tasks, including disease screening, diagnosis, intervention, treatment, patient management, and medical research. Among their array of solutions, InferRead CT Lung specializes in detecting lung nodules from chest CT scans, while InferRead DR Chest focuses on identifying chest abnormalities via X-ray imaging. Moreover, InferRead CT Coronary is tailored for recognizing coronary artery stenosis during coronary CT angiography, and InferRead CT Stroke is adept at triaging hemorrhages from brain CT scans. The company also provides InferRead CT Bone for spotting chest fractures in CT images and InferRead CT Pneumonia for diagnosing and managing pneumonia cases. Beyond these, their offerings extend to InferOperate, which facilitates 3D reconstruction for thoracic, liver, and urological surgical procedures, and InferCare, a tool designed for effective patient management and image follow-up. Additionally, InferScholar acts as an AI-enhanced resource for medical research, further solidifying Infervision's commitment to transforming healthcare through AI technology. This comprehensive suite of solutions positions Infervision as a pivotal player in the evolution of medical practices.
Description
AI plays a crucial role in identifying early-stage cancers, facilitating prompt interventions that enhance survival prospects. Cancer's intricate nature means that each type carries distinct characteristics, packed with extensive data that requires thorough analysis. This is where AI excels, leveraging its capabilities to process complex information, ultimately revealing insights that can significantly aid in cancer treatment strategies. Equipped with precise and relevant data, we take proactive steps in our battle against cancer. By utilizing AI, we are poised to make substantial strides in overcoming this disease. Our AI technology is designed to detect early-stage cancer with remarkable accuracy, achieving detection rates between 97-99%. It proficiently identifies ten of the most prevalent abnormalities found in chest x-rays, thus enhancing one of the most fundamental diagnostic tools. This innovation not only streamlines the radiology workflow but also alleviates the workload for radiologists. Lunit INSIGHT CXR successfully encompasses a wide range of findings, ensuring that we are prepared to tackle the challenges presented by cancer detection and treatment. The future of cancer care looks promising with AI at the forefront of these advancements.
API Access
Has API
API Access
Has API
Integrations
No details available.
Integrations
No details available.
Pricing Details
No price information available.
Free Trial
Free Version
Pricing Details
No price information available.
Free Trial
Free Version
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Deployment
Web-Based
On-Premises
iPhone App
iPad App
Android App
Windows
Mac
Linux
Chromebook
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Customer Support
Business Hours
Live Rep (24/7)
Online Support
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Types of Training
Training Docs
Webinars
Live Training (Online)
In Person
Vendor Details
Company Name
Infervision
Founded
2016
Country
United States
Website
global.infervision.com
Vendor Details
Company Name
Lunit
Country
United States
Website
www.lunit.io/en